4-(chlorosulfonyl)butanoic acid ethyl ester | 319452-60-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-(chlorosulfonyl)butanoic acid ethyl ester
• 英文别名: ethyl 4-(chlorosulfonyl)butanoate；ethyl 4-chlorosulfonylbutanoate
• CAS: 319452-60-3
• 化学式: C₆H₁₁ClO₄S
• mdl: MFCD10011063
• 分子量: 214.67
• InChiKey: WATIBNFNUAUDJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  280.5±23.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(chlorosulfonyl)butanoic acid ethyl ester 在 potassium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 41.25h， 生成 ethyl 4-{[(9-acridinylcarbonyl)-2,4-dimethoxyanilino]sulfonyl}butanoate
  参考文献：
  名称：

  Modulation of the chemiluminescent signal from N10-(3-sulfopropyl)-N-sulfonylacridinium-9-carboxamides

  摘要：

  Acridinium salts 3a-h were synthesized from the corresponding sulfonamides la-h and their chemiluminescence profiles were compared. The quantity of light emitted over the time studied did not correlate well with the pK(a) of sulfonamide leaving group. Rather, steric factors contributed the most to modulating the light output from these compounds. The mesitylsulfonyl substituent of acridinium salt 3d reduced the chemiluminescence signal by 20-fold relative to the reference acridinium salt 3a. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00624-9
• 作为产物：
  描述：

  乙基4-(乙酰基硫代)丁酸酯 在 氯 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 4-(chlorosulfonyl)butanoic acid ethyl ester
  参考文献：
  名称：

  Design of potent inhibitors of human β-secretase. Part 1

  摘要：

  We describe a novel series of potent inhibitors of human beta-secretase. These compounds possess the hydroxyethyl amine transition state isostere. A 2.5A crystal structure of inhibitor 32 bound to BACE is provided.

  DOI：

  10.1016/j.bmcl.2006.09.092

文献信息

• [EN] DEOXYURIDINE TRIPHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DÉSOXYURIDINE TRIPHOSPHATASE
  申请人：UNIV SOUTHERN CALIFORNIA

  公开号：WO2017006270A1

  公开（公告）日：2017-01-12

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  本文提供了dUTPase抑制剂，包括这些化合物的组合物和使用这些化合物和组合物的方法。
• Trisubstituted benzene leukotriene B4 receptor antagonists: Synthesis and structure-activity relationships
  作者：Mitoshi Konno、Takahiko Nakae、Shigeru Sakuyama、Yoshihiko Odagaki、Hisao Nakai、Nobuyuki Hamanaka

  DOI：10.1016/s0968-0896(97)00089-8

  日期：1997.8

  A series of trisubstituted benzenes which demonstrate leukotriene B4 (LTB4, 1) receptor affinity was prepared. Previous trisubstituted benzenes from our laboratory showed high affinity to the LTB4 receptor but demonstrated agonist activity in functional assays. Compound 3a, the initial lead compound of this new series, showed only modest affinity (IC50 = 0.20 microM). However, 3a was a receptor antagonist

  制备了一系列显示白三烯B4（LTB4，1）受体亲和力的三取代苯。我们实验室以前的三取代苯对LTB4受体显示出高亲和力，但在功能测定中显示出激动剂活性。该新系列的初始前导化合物化合物3a仅表现出适度的亲和力（IC50 = 0.20 microM）。但是，3a是一种受体拮抗剂，在高达30 microM时没有明显的激动剂活性。脂质尾部和芳基头部区域的进一步修饰导致3b（ONO-4057）的发现。该化合物无激动剂活性，对LTB4受体具有高亲和力（Ki = 3.7 +/- 0.9 nM）。
• Indoline Derivatives II: Synthesis and Factor Xa (FXa) Inhibitory Activities
  作者：Tetsuji Noguchi、Naoki Tanaka、Toyoki Nishimata、Riki Goto、Miho Hayakawa、Atsuhiro Sugidachi、Taketoshi Ogawa、Fumitoshi Asai、Tomoko Ozeki、Koichi Fujimoto

  DOI：10.1248/cpb.55.393

  日期：——

  Factor Xa (FXa) is well known to play a pivotal role in blood coagulation, so FXa inhibitor is a promising drug candidate for prophylaxis and treatment of thromboembolic diseases. In the course of our research, we have found that (R)-5-[1-(acetimidoyl)piperidin-4-yloxy]-2-(7-amidinonaphthalen-2-yl)-1-(ethanesulfonyl)indoline ((R)-1) showed potent FXa inhibitory activity in vitro. However, single oral administation (RS)-1 showed high toxicity in mice. Among newly synthesized compounds, ((RS)-5-[1-(acetimidoyl)piperidin-4-yloxy]-2-(7-amidinonaphthalen-2-yl)indolin-1-yl}sulfonyl)acetic acid ((RS)-11d) showed more potent FXa inhibitory activity and higher safety than (RS)-1. The R-isoform of compound 11d ((R)-11d) exhibited potent in vitro anticoagulant activity in human and hamster plasma. Orally administered (R)-11d also showed dose-dependent potent anticoagulant activity in hamsters, marmosets and cynomolgus monkeys. Compound (R)-11d with potent anticoagulant activity and high safety is therefore favorable as a novel oral FXa inhibitor.

  因子Xa（FXa）在血液凝固中发挥着重要作用，因此FXa抑制剂是预防和治疗血栓栓塞性疾病的有前景的药物候选者。在我们的研究中，我们发现(R)-5-[1-(乙酰亚胺基)piperidin-4-yloxy]-2-(7-氨基萘-2-基)-1-(乙烷磺酰基)吲哚((R)-1)在体外展示了强效的FXa抑制活性。然而，单次口服给药的(RS)-1在小鼠中显示出高毒性。在新合成的化合物中，((RS)-5-[1-(乙酰亚胺基)piperidin-4-yloxy]-2-(7-氨基萘-2-基)吲哚-1-基}磺酰基)乙酸((RS)-11d)显示出比(RS)-1更强的FXa抑制活性和更高的安全性。化合物11d的R-异构体((R)-11d)在人的和仓鼠的血浆中表现出强效的体外抗凝活性。口服给药的(R)-11d在仓鼠、狨猴和恒河猴中也显示出剂量依赖的强效抗凝活性。因此，具有强抗凝活性和高安全性的化合物(R)-11d是作为一种新型口服FXa抑制剂的有利选择。
• Iridinesulfonamide compound and use method thereof
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US11203586B2

  公开（公告）日：2021-12-21

  An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.

  一种具有异柠檬酸脱氢酶 1（IDH1）抑制活性的铱磺酰胺化合物，其药学上可接受的盐、溶液或水合物，一种药物组合物，以及该化合物或其药学上可接受的盐、溶液或水合物及其药物组合物在治疗 IDH1 突变诱导的癌症中的用途。
• [EN] IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF<br/>[FR] COMPOSÉ IRIDINESULFONAMIDE ET SON PROCÉDÉ D'UTILISATION<br/>[ZH] 丙啶磺酰胺类化合物及其使用方法
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

  公开号：WO2017162156A1

  公开（公告）日：2017-09-28

  具有异柠檬酸脱氢酶1（IDH1）抑制活性的丙啶磺酰胺类化合物，其药学上可接受的盐、溶剂化物或水合物、药物组合物，以及上述化合物或其药学上可接受的盐、溶剂化物或水合物和其药物组合物在治疗IDH1突变诱发的癌症中的用途。